Sanmirna
1 known investors
Sanmirna Therapeutics develops Miristen™, a microRNA-126 inhibitor oligonucleotide therapeutic aimed at eliminating leukemia stem cells in Acute Myeloid Leukemia while sparing healthy blood-forming cells. Licensed from City of Hope, the company has an FDA-approved IND for a first-in-human trial in relapsed/refractory AML and additional pipeline programs targeting colorectal and non-small cell lung cancer.
Investors · 1
Frequently asked questions
- What does Sanmirna do?
- Sanmirna Therapeutics develops Miristen™, a microRNA-126 inhibitor oligonucleotide therapeutic aimed at eliminating leukemia stem cells in Acute Myeloid Leukemia while sparing healthy blood-forming cells. Licensed from City of Hope, the company has an FDA-approved IND for a first-in-human trial in relapsed/refractory AML and additional pipeline programs targeting colorectal and non-small cell lung cancer.
- Who are Sanmirna's investors?
- Sanmirna's investors include NLC.